• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Application of population pharmacokinetic modeling in clinical development of a novel PPI CPRCX: com

Application of population pharmacokinetic modeling in clinical development of a novel PPI CPRCX: com

来源 :第五届定量药理学与新药评价国际会议 | 被引量 : 0次 | 上传用户：zhengpeng19860223
【摘 要】
：
CPRCX is a novel investigated proton pump inhibitor, which shows dramatic success in the management of acid-related disorders.Now this drug is being developed in Phase Ⅱ study in China.In this paper f
【作 者】
：
Xuemei Liu Hongyun Wang Pei Hu Ji Jiang 
【机 构】
：
Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Med
【出 处】
：
第五届定量药理学与新药评价国际会议
【发表日期】
：
2015年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
CPRCX is a novel investigated proton pump inhibitor, which shows dramatic success in the management of acid-related disorders.Now this drug is being developed in Phase Ⅱ study in China.In this paper for the first time, a population pharmacokinetic (PopPK) model of CPRCX was developed to describe phase Ⅰ, and Ⅱa data in healthy volunteers and in patients with duodenal ulcer (DU).
其他文献
Visualized Subject Knowledge-Mapping Study on the Subject of Mapping Study on the Subject of Pharmac
Discipline development of pharmacometrics (PM)Based on traditional pharmacokinetics 1977: Sheiner, Population pharmacokinetics 1980: NONMEM 1980s: Discipline start 1991: Population pharmacokinetics (A
会议
Longitudinal Modeling and Simulation of the Inhaled Corticosteroid (ICS) Effect on Cortisol Circadia
Chronobiology The periodic phenomena in living organisms and their adaptation to solar-and lunar-related rhythms.The CLOCK Disrupted Cortisol Levels Will Lead to…Monitoring Cortisol Change for Safety
会议
Population pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam (CPZ/SUL)(2∶1) in adult p
ObjectivesTo describe PK profiles of CPZ/SUL in HAP patients induced by multidrug-resistant (MDR) P.aeruginosa and Acinetobacter spp.To identify and quantify the covariate effects on the PK profile of
会议
Tolerance study of ulinastatin injection in Chinese healthy volunteers
Objective: To evaluate the safety and tolerance of multi-dose ulinastatin (UTI) for injection in Chinese healthy volunteers.Methods This is a parallel, randomized, double-blind, placebo-controlled, mu
会议
ulinastatin for injectionChinese healthy volunteersmulti-dosesafetytolerance
Population pharmacokinetics of enteral morphine to aid dosing strategy in neonatal abstinence syndro
Background: NAS is a set of physiologic signs of withdrawal resulting from opiate exposure, either in utero or as part of medical care.Although enteral morphine is used to treat NAS, the pharmacokinet
会议
Pharmacokinetic-pharmacodyamic model based colistin and meropenem combinations against Acinetobacter
Background: Hospital infections caused by Acinetobacter baumannii tend to be resistant to various antibiotics.Colistin is increasingly used worldwide as the last-line therapy against A.baumannii.The r
会议
Combining “Bottom-up” and “Top-down” methods to assess ethnic difference in clearance of bitopertin
Background and objectives: Bitopertin (RG1678, RO4917838) is a glycine reuptake inhibitor that is postulated to improve NMDA receptor hypofunction by increasing the synaptic concentration of glycine,
会议
An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for suniti
Background: Breast cancer is one of the leading causes of mortality among women worldwide.As a potent multi-targeted receptor tyrosine kinase inhibitor, sunitinib has shown promising results in clinic
会议
A novel pharmacokinetic model based on the complex elimination of monoclonal antibodies for bevacizu
Background and Purpose: The complex pharmacokinetic (PK) properties of monoclonal antibody (mAb) including a nonlinear pharmacokinetics and a significant individual variation in PK process can not be
会议
BevacizumabModel fittingMonoclonal antibodyNonlinear eliminationPharmacokine
Population Pharmacokinetics of Vancomycin in Septicemia Infants and Its Application in Individualize
Objective: The objective of this study is to develop population pharmacokinetics model of vancomycin in treatment of septicemia in infants under one year old, to investigate factors which have signifi
会议
Infant septicemiaVancomycinPopulation pharmacokineticMonte CarloIndividualiz